GO and KEGG enrichment analyses suggested that bioactive ingredients of GQL affecting the TNF inflammatory signaling and PI3K/AKT pathways were responsible for the main therapeutic effects during T2DM. This evidence concerns the gene AKT1 and type 2 diabetes mellitus.